Antimicrobial Use in Pediatric Leukemia: Insights from St. Jude/PIDS Conference 2025 by Mark Grigoryan
Mark Grigoryan, Pediatric Infectious Diseases Specialist at Muratsan University Hospital Complex, shared a post on LinkedIn:
“March 2025 was a busy month filled with the PIDS Conference, medical exams, and, of course, Match Day!
Let’s start with St. Jude/PIDS Conference 2025. This event is an opportunity to explore the latest research and connect with leading experts in pediatric infectious diseases.
I was honored to present our retrospective study, conducted in collaboration with my pediatric hematologist-oncologist colleagues at Yeolyan Hematology and Oncology Center Saten Hovhannisyan, Mery Petrosyan, Clodet Stepanyans, Garegin Galstyan. Our research focused on non-prophylactic antimicrobial consumption in pediatric leukemia patients experiencing fever and neutropenia. We compared data from 2020 and 2022 at Pediatric Cancer and Blood Disorders Center of Armenia.
Our key finding? Days of therapy per 100 patient days (DOT/100PD) increased from 70.4 in 2020 to 102.5 in 2022, with a DOT/LOT ratio of 1.5 in 2022.
These results highlight the importance of judicious antimicrobial use. One critical strategy is the implementation of an Antimicrobial Stewardship Program – a step toward optimizing treatment while minimizing resistance.
A special thanks to the leadership at Yeolyan Hematology and Oncology Center for their guidance and support Gevorg Tamamyan, Lala Vagharshakyan, Lilit Sargsyan.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023